Adding an anti-inflammatory drug to anti-PD1 checkpoint inhibitor immunotherapy has shown great promise as a new strategy against advanced lung cancer, based on results from a small clinical trial led by investigators at the Abramson Family Cancer Center at the University of Pennsylvania Perelman School of Medicine.
JAK1 inhibition and Anti-PD1 therapy enhance outcomes in advanced lung cancer
- Post author:
- Post published:June 20, 2024
- Post category:uncategorized